 This study found that patients with immune-mediated inflammatory diseases, IMID, who received three doses of SARS-CoV-2 vaccines had similar antibody levels as those who received two doses. Additionally, the antibody levels increased more rapidly after the third dose compared to the second dose. Furthermore, the study showed that the additional doses contributed to stronger and longer-lasting immune responses. This article was authored by Jürgen Jonssen, Ingrid Eageland Christensen, Joe Sexton, and others.